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Phenylalanine hydroxylaseHyperphenylalaninemias are genetic diseases prevalently caused by mutations in the phenylalanine
hydroxylase (PAH) gene. The wild-type PAH enzyme is a homotetramer regulated by its substrate, cofactor
and phosphorylation. We reproduced a full-length wild-type protein and seven natural full-length PAH
variants, p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N, p.A403V, and p.Q419R, and analyzed their biochemical
and biophysical behavior. All mutants exhibited reduced enzymatic activity, namely from 38% to 69% of wild-
type activity. Biophysical characterization was performed by size-exclusion chromatography, light scattering
and circular dichroism. In the puriﬁed wild-type PAH, we identiﬁed the monomer in equilibrium with the
dimer and tetramer. In most mutants, the equilibrium shifted toward the dimer and most tended to form
aggregates. All PAH variants displayed different biophysical behaviors due to loss of secondary structure and
thermal destabilization. Speciﬁcally, p.F382L was highly unstable at physiological temperature. Moreover,
using confocal microscopy with the number and brightness technique, we studied the effect of BH4 addition
directly in living human cells expressing wild-type PAH or p.A403V, a mild mutant associated with BH4
responsiveness in vivo. Our results demonstrate that BH4 addition promotes re-establishment of the
oligomerization equilibrium, thus indicating that the dimer-to-tetramer shift in pA403V plays a key role in
BH4 responsiveness. In conclusion, we show that the oligomerization process and conformational stability are
altered by mutations that could affect the physiological behavior of the enzyme. This endorses the hypothesis
that oligomerization and folding defects of PAH variants are the most common causes of HPAs, particularly as
regards mild human phenotypes.iopterin; CD, circular dichroism;
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Phenylketonuria (PKU, Online Mendelian Inheritance in Man
database: 261600) and its hyperphenylalaninemia (HPA) variantsrepresent the most common inherited disorder of amino acid metab-
olism transmitted by an autosomal recessive mode [1]. The primary
cause of HPA is a dysfunction of phenylalanine hydroxylase (PAH: EC
1.14.16.1). In the liver, this enzymemetabolizes L-Phenylalanine (L-Phe)
to L-Tyrosine (L-Tyr) using (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin
(BH4) as coenzyme. More rarely, forms of HPAs can also be caused by a
lack of the BH4 cofactor due to defective cofactor biosynthesis and
regeneration [2]. Untreated PKU patients present an abnormal pheno-
type, with growth failure, microcephaly, seizures and permanent
neurologic damage because their body ﬂuids contain elevated levels of
L-Phe and its neurotoxic metabolites (phenylpyruvate, phenylacetate
and phenylactate) [1,3].
The major manifestations of the disease, which start at birth, are
prevented by severe dietary restriction of L-Phe [4] and, in selected
cases, by BH4 supplementation, which reduces L-Phe levels and
increases L-Phe tolerance in HPA patients [5]. Several new therapeutic
strategies based on the biochemistry and pathogenetic features of
PKU are currently being investigated [6,7].
1436 M. Cerreto et al. / Biochimica et Biophysica Acta 1812 (2011) 1435–1445The human PAH gene, mapped on 12q23.2, consists of 13 exons
encompassing 171 kb. The full-length PAH cDNA encodes a protein of
about 52 kDa (452 amino acids) that in the mature form is assembled
as a homotetramer. Each subunit consists of three functional domains:
a ﬂexible N-terminal regulatory domain (residues 1–142); a catalytic
domain (residues 143–410) that includes binding sites for iron,
substrate and cofactor; and a C-terminal oligomerization domain
(residues 411–452) with dimerization (residues 411–426) and
tetramerization motifs (residues 427–452) [8] (Fig. 1). The crystal
structure of PAH has revealed that the tetrameric oligomers are
dimers of dimers in which the interaction between the two dimers is
mediated by the C-terminal ‘arm’ [8].
The tetrameric and dimeric forms of PAH are in equilibrium [9,10]
and have different catalytic properties because the tetramer, but not
the dimer, demonstrates a positive kinetic cooperativity with respect
to L-Phe [11]. In particular, substrate activation results in conforma-
tional changes involving the tertiary as well as the quaternary
structure [12] and drives the tetramer–dimer equilibrium toward
the tetrameric form [13]. Further regulation mechanisms require
binding of BH4 [12] and phosphorylation [14].
The clinical and metabolic features associated to HPA are complex
[15] and various genotype–phenotype correlation studies have been
performed [16–18]. In addition, at molecular level, about 600
mutations have been identiﬁed, most of which are point mutations
scattered throughout the whole PAH gene (http://www.pahdb.mcgill.
ca), although frequencies differ among populations and geographic
areas [16–18].
Recombinant variant proteins containing prevalently missense
mutations have been analyzed and characterized in vitro; each
mutation exerts a distinct effect on the behavior of the PAH protein,
which in many cases allows the prediction of the biochemical
phenotype [19–21]. The effects of a speciﬁc mutation on protein
functions have been studied with different approaches, i.e., enzyme
assay, in vivo isotopic studies and in vitro expression. Moreover, the
crystal structures of human and rat PAH [8,22] provided the structural
basis of HPA [23]. It is now established that, inmost HPA cases, the loss
of PAH function is due to decreased stability [21,24], increased
susceptibility toward aggregation and degradation of PAH mutant
proteins [19,24,25], thermodynamic instability [26] and/or folding
efﬁciency [27]. About 75% of PAH mutations, characterized by high
residual activity, have been found to be associated with BH4Fig. 1. Full-length composite model of the PAH monomer structure and distribution of
the HPA-related missense mutations studied in this paper. The N-terminal regulatory
domain is shown in blue, the catalytic domain in red and the tetramerization domain in
green. The Fe ion is shown as a cyan sphere at the center of the catalytic domain; the
mutation sites are marked as yellow balls.responsiveness, both in vitro [28–30] and in vivo [4,5]. It has recently
been speculated that pharmacological doses of BH4 may augment the
conformational stability and the amount of functional PAH [31].
We previously carried out a molecular analysis of the PAH gene in
HPA patients from Southern Italy, and identiﬁed and characterized
several novel mutations [32–34]. In the present study, we analyzed
the wild-type PAH protein and some PAH natural mutants to obtain
further information about the molecular basis of HPAs and the
mechanism of BH4 responsiveness. To this purpose, we reproduced,
by in vitro mutagenesis, the wild-type and seven natural variants of
PAH: p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N, p.A403V, and
p.Q419R, and characterized the biophysical–biochemical properties of
the above-mentioned puriﬁed full-length proteins in order to
understand the impact of each mutation on the activity, oligomeric
structure and stability of PAH. In addition, we investigated the
mechanism underlying BH4 responsiveness using p.A403V, which is
one of the most frequent mutations in our geographic area [32], and is
associated with a BH4-responsive mild phenotype [35].
2. Material and methods
2.1. Construction of PAH expression plasmid and site-directed
mutagenesis
PAHwild-type andmutant constructs were obtained by modifying
the pMAL Xa PAH plasmid, kindly provided by Drs CR. Scriver and P.
Waters (McGill University-Montreal Children's Hospital Research
Institute, Montreal, Canada), to digest the fusion protein MBP-PAH
with enterokinase (Ek) [9]. The Ek site was inserted downstream the
sequence encoding the factor Xa site, by site-directed mutagenesis
using the primers 5′gatgacgatgacaagtctactgcggtcctgg3′ and 5′
gccctaactcccttccctactgctactgttc3′ and the Quick Site-directed muta-
genesis kit (Stratagene, CA, USA). GFP was ampliﬁed by PCR from
pEGFP-N1 (Clonetech, CA, USA) using the primers: 5′acattaggtac-
cagccatggtgagcaagggcgag3′ and 3′ gtagatgaattctccaccacccttgtacagctcg
5′ and cloned into pcDNA3 (Invitrogen, Carlsbad, CA) using Kpn1
and EcoR1 sites. PAH cDNA was ampliﬁed from pMAL Xa Ek PAH
by using the primers: 5′catcattgaattctccactgcggtcctgg3′ and 3′
cgtaatgcggccgcttactttattttctggag 5′ and cloned downstream GFP,
using EcoR1 and Not1 sites. Sequence analysis conﬁrmed the correct
frame.
Mutations were introduced into pMAL Xa Ek PAH and pCDNA3-
GFP-PAH using mutagenic primers and the Quick Site-directed
mutagenesis kit (Table 1). The modiﬁed plasmid and the mutant
clones were sequenced to verify the introduction of each single
mutation. Commercial MBP was obtained from New England Biolabs
(Ipswich, MA, USA).
2.2. Expression, puriﬁcation and N-terminal sequencing of the
PAH protein
pMAL Xa Ek PAH expression plasmids were transformed into
Escherichia coli BL21 cells and the colonies were selected using Luria-
Broth plates with ampicillin (0.1 mgmL−1). Bacteria were grown to
2×108 cells/mL (A600nm~0.5) and overexpression of wild-type and
variant MBP-PAH fusion proteins was induced with 1 mM isopropylthio-
β-D-galactoside (IPTG) for 16 h at 37 °C. Cells were harvested by
centrifugation and treated according to the instruction manual of the
pMAL protein fusion and puriﬁcation system (New England Biolabs). The
fusion proteinwas digested overnight at room temperaturewith Ek (New
England Biolabs) to obtain wild-type and mutant forms of PAH without
the MBP tag, using 0.5 ng of enzyme for each 50 μg fusion protein. The
mixturewas then applied to ahydroxyapatite column (1 cm×10 cm, Bio-
Rad Laboratories, CA, USA) and subjected to several washes with 20 mM
sodiumphosphate, 200 mMNaCl (pH7.2). Proteinswere thenelutedwith
0.5 MNa phosphate, pH 7.2 and subsequentlyMBPwas isolated from the
Table 1
The seven mutant forms of PAH reproduced in vitro as recombinant products and analyzed. The primer pairs used to produce the pMAL Xa Ek PAH plasmid.
Mutant forms of PAH Mutagenic primers (forward) Mutagenic primers (reverse)
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by size-exclusion chromatography with a HiLoad 16/60 Superdex 200
column (GE Healthcare, UK). Protein concentrations were determined
spectrophotometricallywith the use of the absorption coefﬁcient A280 or
the dye-binding Bradford assay (Bio-Rad Laboratories). The N-terminal
aminoacid sequenceofPAHwasdeterminedbyEdmandegradationonan
automated Procise H49 sequencer (Applied Biosystems, MA, USA).
It has been reported [36] that, during the various steps of
recombinant protein production, some labile Asn residues are
deamidated: however, any possible deamidation of these residues,
which would in the activity assay produce substrate inhibition, would
most likely be the same in the presence of wild-type and of the variant
forms of PAH we have employed.
2.3. Concentration and storage of proteins
The concentration of proteins was determined both by the micro
BCA protein assay and spectrophotometrically. The ﬁnal protein
concentration was measured based on optical density at 280 nm
using, for the extinction coefﬁcient, a value of 49,780, 66,350 and
115,630 M−1 cm−1 for PAH, MBP and the fused wild-type MBP-PAH
respectively, deduced from the amino acid composition of the protein.
We used a SpeedVac concentrator (Thermo Scientiﬁc, Rockford, IL,
USA) to concentrate the protein solutions because ultra-ﬁltration led
to considerable sample loss. All protein samples, if not utilized within
few days, were stored at −20 °C in their elution buffer (see below).
2.4. PAH activity and thermal inactivation assay
Enzymatic activity analysis was carried out on a whole equilibrium
mixture of oligomeric species of puriﬁed full-length wild-type and
mutant PAH (see Supplementary Table S1). The activity was assayed
in the presence of 0.25 μCi L-[14C] Phe (Amersham, Buckinghamshire,
UK; 460 μCi/mmol); 0.25 mM cold L-Phe, 1.3 units of beef liver
catalase; 0.8 mM BH4; 250 mM Tris HCl pH 7.8, 1 μg of protein;
ﬁnal volume: 100 μL. The reaction was conducted at 25 °C with
an incubation time of 1 h [32–34]. After centrifugation at room
temperature andmaximum speed, an aliquot of each supernatant was
applied on a thin-layer chromatography system and the amount of
[14C] radio-labeled L-Phe converted to [14C] radio-labeled L-Tyr was
measured. The mean PAH activities were calculated from three sets of
experiments. The residual activities of mutant PAH enzymes were
expressed as a percentage of wild-type enzyme activity. The same
assay was used for the thermal inactivation analysis of the wild-type
protein and of the p.F382L mutant. Thermal inactivation of both
proteins was determined by measuring the decay of tyrosine
production as a function of temperature in the 32–58 °C range.
2.5. Electrophoresis and immunoblotting
SDS/PAGE was performed at 100 V (2 h) in a 10% (w/v)
polyacrylamide gel. The puriﬁcation of all proteins was veriﬁed after
staining with Colloidal Coomassie. The absence of MBP contamination
in all preparations was determined by western blot analyses.Immunoblotting was performed using afﬁnity-puriﬁed rabbit anti-
hPAH [32–34] and mouse anti-MBP (New England Biolabs) as primary
antibodies. The enhanced chemiluminescence system from Amersham
(GE Healthcare) was used for immunodetection.
2.6. Size-exclusion chromatography with multiangle light scattering
Size-exclusion chromatography (SEC) was performed using Akta
FPLC chromatography equipment (GE Healthcare) on a Superdex 200
10/300 GL column. The column was previously calibrated for
molecular mass using a Gel Filtration High Molecular Weight
calibration kit (GE Healthcare) constituted by ovalbumin (44 kDa),
conalbumin (75 kDa) and aldolase (158 kDa). Before each run, the
column was equilibrated with at least two column volumes of elution
buffer and each run was performed at both 4 °C and room
temperature (20–23 °C). The elution buffer was Tris–HCl 20 mM pH
7.4, NaCl 100 mM (buffer A) and, in a few cases, Na-phosphate 20 mM
pH 7.0, KF 150 mM (buffer B).
The eluent ﬂow was 0.5 mL min−1. Only freshly prepared or
recently defrosted proteins were loaded on the column because
storage at 4 °C for more than one week led to sample aging. A total of
0.1÷0.2 mg of proteins were loaded. At room temperature, the
elution proﬁle was monitored at three UV absorption wavelengths
(280 nm, 215 nm and 258 nm). At 4 °C, UV absorption was measured
only at 280 nm. The chromatograms were deconvoluted by Unicorn
software, supplied with the FPLC device, to calculate the percentage of
single species. All chromatograms were normalized in the (0.0÷1.2)
range.
At roomtemperature, size-exclusionchromatographywithmultiangle
light scattering (MALS) experiments was carried out with the AKTA
systemcoupled toa three-angle (45°, 90° and135°)WyattMinidownEOS
light scattering instrument linked to a Wyatt Optilab refractometer
(Wyatt Technology Corp., Santa Barbara, CA). These experiments served
to determine the sizes of oligomers of wild-type and mutant PAH.
Molecular masses, polydispersity and root mean square radius
calculations were made by ASTRA software, which is supplied with
the light scattering device, using a dn/dc value of 0.185 mL g−1.
2.7. Circular dichroism
Circulardichroism(CD) analysiswasperformedoncommercialMBP,
on the fused wild-type MBP-PAH tetrameric sample and on the most
abundant species of cleaved PAH proteins after SEC puriﬁcation. In the
case of the cleaved wild-type PAH, CD experiments were performed
with both the tetrameric form and the whole equilibrium mixture. A
2-day dialysis at 4 °C against Tris–HCl 20 mM pH 7.4 (buffer C) was
conducted to eliminate NaCl before CDexperiments. All CD spectrawere
recorded with a Jasco J-810 spectropolarimeter equipped with a Peltier
temperature control system(model PTC-423-S). The spectropolarimeter
was calibrated with an aqueous solution of D-10-(+)-camphorsulfonic
acid at 290 nm. The molar ellipticity per mean residue, [θ] in deg cm2
dmol−1, was calculated from the equation [θ]=[θ]obs mrw (10 l C)−1,
where [θ]obs is the ellipticity measured in degrees, mrw is the mean
residue molecular weight (111.5 Da), C is the protein concentration in
Fig. 2. Enzymatic activity of the PAHmutants expressed as percentage of wild-type PAH
activity. The activity was measured by the amount of [14C] Tyr produced by [14C] Phe as
analyzed by thin layer chromatography. Mean values and the standard deviation
derived from three sets of independent experiments for each construct are shown
expressed as percentage of wild-type PAH activity. The experimental assay conditions
are reported in Section 2.4.
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(ultraviolet) measurements (190–260 nm) were carried out at 20 °C
using a 0.2 cmoptical path length cell and a protein concentration in the
range 0.10–0.15 mg mL−1. CD spectra, recordedwith a time constant of
4 s, a 1-nm bandwidth, and a scan rate of 20 nmmin−1, were signal
averaged over at least three scans. The baseline was corrected by
subtracting the buffer spectrum. Thermal denaturation curves were
recorded over the 20–80 °C temperature range and by monitoring the
CD signal at 222 nm.After preliminary trialswithin the scan rate interval
of 0.5÷2.0 °C min−1, all curves were recorded using a 0.2-cm path
length cell and a scan rate of 1.0 °C min−1. Irreversibility of the
denaturation was veriﬁed by recording, after cooling to 20 °C, the
spectra of samples subjected toaﬁrst temperature scan.All denaturation
curves were normalized in an interval of 0.0÷1.0. The Tm values were
determined from the ﬁrst derivatives of the denaturation curves after
noise reduction by using the standard analysis program provided with
the instrument.
2.8. Cell culture
HeLa cellswere grown inD-MEMhigh glucosemedium (Invitrogen)
containing 10% heat inactivated fetal bovine serum (Invitrogen), 1%
penicillin/streptomycin, at 37 °C in 5% CO2. Transfections of both wild-
typePAHand thep.A403Vmutantwere carriedout using theProFection
Mammalian Transfection System (Promega, WI, USA) in accordance
with the manufacturer's protocol. Cells were plated on 35-mm glass
bottom dishes (MatTek, MA) for imaging.
2.9. Confocal microscopy and number and brightness analysis
Constructs containing GFP-PAH fusion proteins were transfected
in HeLa cells and experiments were started 18 h after transfection. To
evaluate BH4 responsiveness, transfected cells were treated with
60 μM BH4 in aqueous solution. Analyses were performed 6 h later.
Number and brightness (N&B) analysis was performed according to
Gratton and colleagues [37,38] using a Zeiss LSM 510 META confocal
microscope. Cells grown for 4 days on bottom glass dishes were
imaged in vivo in CO2-independent medium (150 mM NaCl, 5 mM
KCl, 1 mM CaCl2, 1 mMMgCl2, and 20 mM Hepes, pH 7.4). Fifty frame
time series were acquired with a LSM 510META equipped with a plan
apo 63× oil-immersion (NA 1.4) objective lens using the following
settings: 488 nm Argon laser, 25% of output power, 1.5% transmission,
505–550 nm emission, gain equal to 850, offset 0.1, and digital gain 1.
Scanning parameters were: 512×512 frame window, 25.61 μs/pixel
dwell time, no average, zoom 6×, ROI (x,y) 256×64, and pinhole
corresponding to 1 μmoptical slice. Data from each cell were analyzed
with the simFCS software (Globals Software, East Villa Grove, IL
61956, USA). Brieﬂy, data analysis was performed pixel-by-pixel over
time to calculate variance and average intensity. Correction was
applied to take into account the analog detection of ﬂuorescence by
the photomultiplier tubes of the confocal microscope. Brieﬂy, the
correction parameters S, offset and sigma0 were determined, for each
experiment, by plotting the measured average intensity (bIN) vs
average variance (bVarN) of 50 frame time series acquired using same
settings as above, but setting 4 different values of laser transmission
percentages. Moreover, ﬁlters and beam splitters were conﬁgured to
obtain reﬂection images to detect the deﬁned amount of light
originating directly from the laser. The obtained plots were linearly
interpolated and the equation of straight line (R≥0.99) was used to
extract the parameters S and offset based on the following equation:
bVarN=S∗b IN+offset∗S. The parameter sigma0 was estimated from
time-series acquired with laser off, as the half maximum width of the
histogram peak of the “dark”-counts. Its value was constantly lower
than 0.1, and consequently was approximated to zero in all the
calculations. Brightness (B) was calculated pixel by pixel from thefollowing equation B=V(x,y)/(S∗ Ix,y), where I = Im-offset (Im:
measured average ﬂuorescence).
The number of molecule subunits constituting each oligomer was
calculated with the following calibration procedure: the brightness of
monomeric GFP and of GFP-based molecules made by two or three GFP
moieties fused in tandeminexpressionvectorpcDNA3.1andexpressed in
HeLa cellsweremeasuredwith the same experimental settings described
above. The measured B values for monomeric, dimeric and trimeric GFP
and the corresponding number of subunits were linearly interpolated to
obtain the experimental equation describing the dependence of
brightness on thenumberofGFP subunits: B=k×nsub+c. This equation
was used to calculate the unknown number of GFP subunits correspond-
ing to the measured brightness. The following formula B=sum (Bi2 ni)/
sum(Bi ni) provides the brightness ofmultiple species (Bi)whose number
is ni in a single pixel, is combined in the measured brightness (B). This
formula is used to interpret non integer subunit values obtained by the
above procedure.
2.10. Structural analysis
The effect of themutations on the 3D structure was investigated by
analyzing the structural environment of each substituted residue in
the PAH crystal structures deposited in the Protein Data Bank (PDB).
Since no crystal structure of any full-length enzyme is available,
various models were used: tetrameric human PAH lacking residues
1–117 (pdbcode 2pah); dimeric truncated human PAH lacking
residues 1–117 and 425–452 (PDB code 1kw0); and the dimeric rat
PAH, from residue 19 to 427 (pdbcode 1phz), which encompasses the
regulatory domain. A composite monomeric model that included the
three domains was built by superimposing the secondary structure
elements of the respective catalytic domains of the rat (1phz) and
human structures (2pah and 1kw0). The structural superposition was
performed using the program O [39].
3. Results
3.1. Enzymatic activity analysis of wild-type and mutant forms of PAH
Wemeasured the enzymatic activity of the equilibriummixture of
the wild-type and mutant forms of PAH to investigate the effect of the
mutations on catalytic activity. As shown in Fig. 2, the residual
activities of the mutant PAH enzymes, expressed as a percentage
of wild-type enzyme activity, were: 38±3% (p.I65M), 48±14%
(p.N223Y), 60±12% (p.R297L), 69±11% (p.F382L), 58±9%
(p.K398N), 43±4% (p.A403V) and 63±5% (p.Q419R). In our
conditions, we found in multiple experiments that isolated oligomeric
species are not stable and evolve toward the equilibriummixture (see
1439M. Cerreto et al. / Biochimica et Biophysica Acta 1812 (2011) 1435–1445also below under Section 3.2); hence the activity of the isolated
tetramers and dimers was not possible to be measured with accuracy.
3.2. Oligomerization equilibrium of wild-type and mutant forms of PAH
The oligomerization equilibrium for the fused MBP-PAH protein,
the puriﬁed cleaved wild-type protein, and the missense mutants was
analyzed by SEC (Fig. 3a,b). SEC runs were carried out at both 4 °C and
room temperature. The elution proﬁle was essentially the same at
both temperatures, therefore only the data at room temperature are
reported. Unless speciﬁed otherwise, SEC measurements were carried
at a constant pH of 7.4 (buffer A). The SEC proﬁles revealed that wild-
type and most of the mutant forms of PAH elute as tetramers and
dimers although monomers and aggregates are also present,
depending on the mutation of the protein. Fig. 3a shows the SEC
proﬁles of proteins in which the tetramer is the most abundant
species, i.e., the fused protein, the cleaved wild-type PAH and mutant
p.R297L. Fig. 3b shows the proﬁles of the wild-type PAH (as reference)
and of mutants p.I65M, p.N223Y, p.F382L, p.K398N, p.A403V and
p.Q419R in which dimer is the dominant species. The peaks
corresponding to tetramer, dimer and monomer species elute at
11.5 mL, 13.1 mL and 14.7 mL respectively (Fig. 3a,b).Fig. 3. Chromatographic proﬁles of the PAH natural variants and immunoblotting of wild-ty
and normalized in the 0.0÷1.2 interval. All curves are shifted along the ordinate axis by 0.05n
and other mutant recombinant PAH proteins. All curves are shifted along the ordinate axis by
the single curves. c)Western blot analysis using the anti-PAH antibody of each of the fraction
forms, possibly multimeric; peak T) tetramer; peak D) dimer; peak M) monomer. Western b
MBP antibodies.The presence of the PAH protein was conﬁrmed in each of the
fractions obtained by SEC (Fig. 3a) after separation by SDS/PAGE and
Western blot analysis using anti-PAH serum (Fig. 3c). This result
demonstrates the existence of a monomeric form of the PAH enzyme.
This formwas probably underestimated in previous studies because it
was masked by MBP. Western blot analysis also showed that samples
did not contain MBP after cleavage (Fig. 3c).
The percentage of PAH oligomeric species is reported in Fig. 4 (see
also Supplementary Table S1). The tetramer and dimer species of the
wild-type PAH were separately collected and stored for less than one
week at 4 °C. Subsequently, SEC analysis of tetramers and dimers
showed that the tetramer shifts back toward the dimer and the
monomer, while the dimer is fairly stable, since about 90% of the
protein applied was recovered in the dimeric form (data not shown),
according to literature data [21].
All chromatographic runs were done in conjunction with MALS.
The masses resulting from MALS measurements in wild-type PAH
mutants were 203 kDa (within 1%) and 102 kDa (within 3%) for
tetramer species and dimer species, respectively. Because of the small
quantities of monomer, we were not able to calculate its molecular
mass. A representative proﬁle of wild-type PAH obtained from MALS
is shown in Fig. 5.pe PAH. a) Size exclusion chromatographic (SEC) runs carried out in buffer A (see text)
, n integer (1≤n≤5), with respect to the wild-type PAH curve. b) SEC runs of wild-type
0.05n, n integer (1≤n≤5), with respect to the wild-type PAH curve, to better visualize
s in panel a obtained fromwild-type (depicted as a black curve in a); peak A) aggregated
lot analysis of the wild-type PAH monomer (peak M of panel a) with anti-PAH or anti-
Fig. 4. Percentage of the molecular species of the recombinant wild-type PAH protein and its mutants. The histograms indicate a) the percentage of tetramers and dimers, and b) the
percentage of aggregate and monomers of recombinant wild-type PAH, MBP-PAH, p.I65M, p.N223Y, p.R297L, p.F382L, p.K398N, p.A403V and p.Q419R. All data with standard
deviations were calculated on at least triplicate runs carried out at 20 °C.
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The dominant oligomeric species of wild-type PAH and mutants,
collected after gel ﬁltration and dialyzed against buffer C, were
analyzed by CD. The CD spectra of all samples were recorded in the
far-UV region (190–250 nm), in buffer C, pH 7.4, at 20 °C. Fig. 6a
shows the normalized spectra for wild-type PAH and selected
mutants, together with the spectrum for the fused wild-type MBP-
PAH. In the spectra of Fig. 6a, the maximum centered at 195 nm and
the two broad minima centered at 208 and 222 nm are indicative of
the presence of both α and β secondary structure elements. The
spectra proﬁles do not differ signiﬁcantly from each other, but the
molar ellipticity of all the mutants is much lower than that of wild-
type enzyme. Therefore, these spectra provide evidence for local
unfolding of the mutants.
We also recorded the thermal denaturation curves in the
20÷80 °C temperature range by monitoring the molar ellipticity at
222 nm (Fig. 6b) of the most abundant oligomeric species of cleaved
PAH proteins (Figs. 3a,b; 4, Supplementary Table S1). The far-UV CD
spectra of denatured species of all samples at 80 °C are typical of
random coil (data not shown). The spectrum of cooled samples after
denaturation is virtually identical to that of the denatured protein atFig. 5. SEC-MALS analysis of wild-type PAH. Representative proﬁle of wild-type PAH
obtained from light scattering and refractive index detectors. The molecular mass is
shown. The experimental data are represented by squares and the ﬁtting of
experimental data is shown by a red line.80 °C (data not shown), thereby conﬁrming the irreversibility of the
unfolding process, as previously reported [24,40]. In the case of the
wild-type PAH, the denaturation curve of the equilibriummixturewas
also recorded; for comparison purposes, this curve and that of the
tetramer are shown in Fig. 6c. It is clear that the denaturation process
depends on the oligomeric species.
The sigmoidal denaturation curve obtained with the fused wild-
type MBP-PAH protein shows two inﬂection points, with a plateau,
corresponding to the two melting temperatures of the two proteins.
Visual inspection of the denaturation curves (Fig. 6b) of the cleaved
PAH proteins shows a sigmoidal shape with a single inﬂection point.
Differently, a detailed analysis of the curves through the ﬁrst
derivatives, revealed two midpoints corresponding to two transitions
(data not shown), according to literature data [40]. As shown in
Table 2, the melting temperatures of the PAH proteins range from 33
to 57 °C. The thermal denaturation curve of mutant p.F382L is
signiﬁcantly shifted to lower temperatures with respect to the wild-
type PAH (Fig. 6b). Therefore, we carried out the thermal inactivation
assay of the wild-type PAH and the p.F382L mutant at temperatures
between 32 and 58 °C (Fig. 6d). Consistently, the p.F382L mutant was
much more temperature sensitive than the wild-type enzyme. In fact,
under these conditions a lower amount of Tyr was produced (Fig. 6d),
and the half-inactivation temperature was close to 44 °C, which well
agrees with the value of Tm2=43.6 °C obtained by CD. These ﬁndings
show that the stability of speciﬁc mutants, such as p.F382L, can
markedly diverge from that of the wild-type protein.
3.4. N&B analysis
Confocal microscopy observation of cells expressing GFP-wild-
type PAH and GFP-A403V fusion proteins revealed a cytoplasmic
localization of PAH and its mutant p.A403V, as expected (Fig. 7a,b). No
ﬂuorescence was detected in the cell nuclei. To estimate the number
of subunits constituting wild-type PAH and the p.A403V mutant at
steady state in live cells, the recently developed N&B technique was
performed on cells expressing the fusion proteins treated and not
with BH4 for 6 h. The “brightness” of the GFP-wild-type PAH fusion
protein was 1.091 and 1.099 upon BH4 treatment, which, at the t-test,
was not signiﬁcantly different from values obtained without BH4
treatment. On the contrary, in cells expressing the GFP-A403V fusion
protein there was a statistically signiﬁcant (pb0.001) shift of
brightness from 1.047 without BH4 to 1.094 upon its addition.
Fig. 6. CDmeasurements. a) Far-UV spectra recorded in buffer C (see text) at 20 °C. b) CD-monitored thermal unfolding curves in the 25–80 °C temperature range. The change of the
molar ellipticity at 222 nm was monitored versus the temperature. The most abundant oligomeric form was considered for each PAH protein. c) Thermal denaturation of the
tetrameric form and of the equilibrium mixture of cleaved wild-type PAH. d) Thermal inactivation assay of wild-type and F382L PAH. Proteins were incubated at increasing
temperatures and the amount of produced tyrosine was determined.
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subunits that constitute each PAH oligomer at steady state, namely
wild-type and p.A403V before and after BH4 administration (see
Material andmethods for details). Brieﬂy, a calibration curve (number
of subunits vs brightness) was constructed using reference GFP-basedTable 2
Melting temperatures inferred by ﬁrst derivative of unfolding curves.a
Forms of PAH Tm1±1.0 (°C) Tm2±1.0 (°C)
Wild-type PAH 52.2 57.6
MBP-PAH 52.0 57.5







All experiments were conducted in buffer C (see Material and methods).
a See also Fig. 6b.molecules constituted by 1, 2 or 3 GFPmonomers andmeasuring their
brightness in the same experimental conditions used above. The
reference curve obtained (which was perfectly linear) was used to
extrapolate the unknown number of subunits from the brightness of
GFP-PAHs. The wild-type PAH conserved an average number of
subunits (see Material andmethods for deﬁnition of “average number
of subunits”) equal to approximately 3.1, which reﬂects the presence
of tetramers and dimers in equilibrium. The addition of BH4 did not
affect this number. Differently, exposure of the A403V-PAH mutant
form to BH4 caused the subunit number to increase from 2.4 to 3.1,
this latter being the same as that of the wild-type enzyme (Fig. 7c).
4. Discussion
4.1. The oligomerization equilibrium is shifted toward the dimeric form
in PAH mutants
To characterize the oligomeric state of PAH in solution, we
performed SEC with on-line detection of LS and refractive index
signals. This approach allowed us to measure the molecular mass of
Fig. 7. N&B analysis. a) Confocal microscopy images of cells expressing GFP-wild-type PAH protein and b) GFP-p.A403V mutant protein. c) Histograms showing the oligomeric state
of both GFP-wild-type PAH and GFP-p.A403V mutant in untreated (blue bars) and BH4-treated (red bars) cells. Asterisks above the bars indicate statistical signiﬁcance for the
p.A403V mutant protein.
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composition and elution volume. The operative conditions used in the
SEC experiments were the same for all samples. No substrate, cofactor
or any other compound was added and only a buffer at physiological
pH (buffer A; pH 7.4) was used because a lower pH and the addition of
L-Phe can affect the oligomeric equilibrium [10].
In line with previous data [10,21,24], the SEC proﬁle of the fused
wild-type MBP-PAH protein revealed that tetramer was the dominant
species (88.4%), whereas the dimeric form was less abundant and the
monomeric form was absent. Differently, all three species were
obtained in the cleaved full-length wild-type enzyme (see Fig. 4 and
Supplementary Table S1 for the relative percentages). The observation
of three distinct peaks demonstrates that self-association of mono-
mers or dimers is slow on the time scale of separation. Previous
studies showed that both fused and truncated/cleaved forms of wild-
type and mutant enzymes consist of an equilibrium mixture of
dimeric and tetrameric species in a ratio that depends on the protein
nature and on the experimental conditions used [10,24].
Only in a few cases in which proteins were expressed in a coupled
in vitro transcription–translation eukaryotic system [41,42] was the
monomeric form also detected. Here, we report evidence that a
monomer species occurs in the equilibriummixture of PAH albeit in a
low amount. The presence of a monomer species may have been
underestimated in previous studies for several reasons: i) because of
its low abundance, ii) because the fused protein was analyzed [24] or
iii) because the cleaved wild-type PAH was analyzed in the presence
of MBP which co-elutes with the PAH monomer [10]. Western blot
analysis (Fig. 3c) and re-chromatography of the isolated tetramer of
wild-type PAH, which regenerate the dimer and the monomer peak
(data not shown), indicate that the monomer contributes to the
equilibriummixture. The equilibriummixture of the PAH enzyme can
be described as follows: 4M⇆2D⇆T.The oligomerization process of the mutants is clearly disturbed by
the mutation, except in the case of mutant p.R297L that has a SEC
proﬁle similar to that of the wild-type enzyme although it lacks a
monomer (Fig. 3a). For all the other mutants (p.I65M, p.N223Y,
p.F382L, p.K398N, p.A403V and p.Q419R), the equilibriumwas shifted
toward the dimeric enzyme (Fig. 3b). In any event, all mutants present
a reduced activity of the enzyme because of the diverse composition
of the equilibriummixture. This conﬁrms that oligomerization defects
of PAH variants are one of the most common causes of HPAs.
4.2. Thermal stability and defect at the secondary structure level of
PAH mutants
The CD spectrum of wild-type PAH is characterized by typical
ﬁngerprints of α/β proteins (Fig. 6a), in line with the known 3D
structure [43]. Despite the similarity of CD spectra proﬁles in thewild-
type and mutant forms of PAH, the latter present a partial loss of
secondary structure with respect the wild-type folded structure, their
molar ellipticity being signiﬁcantly decreased (Fig. 6a). This loss
occurs for all the mutants except for mutant p.R297L in which the loss
is less pronounced. Therefore, the CD spectra have provided evidence
for a folding defect at secondary structure level. To characterize
further all the PAHmutants, we estimated the α-helical content using
the equation of Richardson and Makhatadze [44]. The calculations
showed a progressive decrease of the α-helical content of the PAH
mutants (see Supplementary Table S2).
Thermal denaturation of all the PAH proteins proved to be an
irreversible process as previously reported [40]. Therefore, the
thermodynamic features of the enzyme cannot be further character-
ized. As expected for the wild-type MBP-PAH fused protein, the two
steps in the sigmoidal curve correspond to two independent
unfolding processes for the two proteins. Indeed, the two melting
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collapse of PAH (52.0 °C) and MBP (57.5 °C), respectively (see also
Supplementary data for details).
Earlier differential scanning calorimetry, ﬂuorescence and CD
experiments indicated that, upon heating, two partially overlapping
transitions occur with an apparent melting temperature Tm1 of about
46 °C and a Tm2 of about 54 °C, respectively [14,40]. Apart from rare
exceptions, two transitions were identiﬁed also in the mutants. Their
melting temperatures diverged from that of wild-type PAH within a
range from −6 to +2 °C [24,45]. On the other hand, unfolding
experiments conducted on the truncated PAH (aa 112–452) revealed
only one cooperative transition centered at about 54 °C [40].
Therefore, the ﬁrst transition was interpreted as a denaturation of the
N-terminal regulatory domain and the second, partially overlapping
transition as a denaturation of the catalytic-tetramerization domain
[40].
Unfolding experiments were carried out for wild-type PAH and
mutants in buffer C and the ellipticity at 222 nm was monitored as a
function of temperature. Two overlapping transitions occurred for the
wild-type PAH and all the mutants. For the wild-type PAH, the Tm1
and Tm2 were 52.2 °C and 57.6 °C, slightly different from previous
reports [24,40,45]. This discrepancy is due to the species studied. If the
denaturation process is followed using only the PAH tetramer, as in
our case, the melting temperatures are Tm1=52.2 °C and
Tm2=57.6 °C. On the other hand, if all the species present in the
oligomerization equilibrium are considered, the Tm1 well agrees with
that reported previously (Tm1=46.1 °C) (Fig. 6c) [24,40,45]. To verify
that the unfolding process depends only on the oligomerization
equilibrium, we carried out unfolding experiments in the same buffer
and scan-rate conditions used in previous studies (buffer B, scan-rate
0.7 °C/min) [40,45], and obtained a Tm1 and Tm2 of 52.0 °C and 54.8 °C,
respectively. Indeed, a small destabilization has been reported for
most of the previously described mutants, as shown by a decrease in
ΔTm of about a couple of degrees. There are only a few instances
where ΔTm decreases down to ~6 °C [45]. For example, Tm1 and Tm2
decreased by as much as 42.6 °C and 52.0 °C and 40.7 °C and 50.2 °C,
respectively in the non-natural mutants p.N223D and p.T427P with
respect to wild-type enzyme Tm1 and Tm2 [45].
Themelting temperatures of mutants p.I65M and p.N223Y indicate
a very marginal stability gain, being only a couple of degrees higher
with respect to the wild-type enzyme (Table 2). Furthermore, the
denaturation curves of p.R297L and p.Q419R are similar, and the
denaturation slopes differ only slightly from that of the wild-type
enzyme, which indicates that the thermal stability is hardly affected.
Formutants p.K398N and p.A403V, however, the Tm1 is about 6° lower
and the Tm2 about 2–3° lower with respect to the wild-type, thereby
indicating a loss of stability. Interestingly, the Tm1 (33.0 °C) and Tm2
(43.6 °C) of mutant p.F382L are about 20 °C and 14 °C lower with
respect to those of the wild-type enzyme, which indicates that this
enzyme variant has a high thermal structural instability.
The results of thermal denaturation experiments of the p.F382L
mutant suggest that the replacement of L-Phe by L-Leu at position 382
leads to temperature-dependent functional alterations. These results
were conﬁrmed by the thermal inactivation assay performed on the
p.F382L mutant and, for comparison, on the wild-type PAH. Indeed,
the half-inactivation temperature obtained for this mutant (~44 °C)
well agrees with the Tm2 of 43.6 °C obtained by CD (Fig. 6b and d,
Table 2).
4.3. Mapping the mutations to search for structural alterations
For the present study, we built a composite model of the full-
length human enzyme and used it as a template for structural analysis
of the wild-type and mutant proteins. Mutations p.I65M and p.Q419R
fall in the regulatory and tetramerization domain, respectively;
mutations p.N223Y, p.R297L, p.F382L, p.K398N and p.A403V fall inthe large catalytic domain. All mutations are far from the active and
cofactor binding sites. All, except mutations at positions 65 and 403,
are located on the surface of the molecule in hydrated regions. In
Fig. 1, the position of the seven mutations is drawn on the monomer
structure. There are four previously identiﬁed variants at codon 65
(p.I65T, p.I65V, p.I65N, and p.I65S). The PAH database contains in
vitro expression data only for p.I65T, namely, increased proteolytic
degradation in pulse-chase experiments, increased aggregation and
decreased solubility. The residual activity of the I65T/V mutants,
tested in different in vitro systems, was about 21–29% (http://www.
pahdb.mcgill.ca).
Ile65 is located in a hydrophobic environment of the regulatory
domain. In the mutant enzyme p.I65M, the Ile change to a somewhat
larger but differently shaped Met may distort the hydrophobic
packing of the region [30]. In addition, Ile 65 makes a favorable
interaction with the catalytic domain of another subunit within the
dimer (the Ile65 oxygen atom is hydrogen-bonded to the hydroxyl
group of Tyr 216). As a result, both the tertiary structure and the
quaternary structure are perturbed. These data are in line with the
dimer abundance (Fig. 4 and Supplementary Table S1).
Asn223 is located in a solvent exposed loop [46]. In mutant
p.N223Y the structural perturbation is mainly due to tyrosine solvent
exposure that may affect the function. It has been proposed that this
residue is embodied in an intra-domain hinge bending region [45]
that is involved in the conformational transition induced by substrate
binding. Overall, its properties are similar to those of the wild-type
enzyme, except that the dimeric form is favored over the tetramer.
Mutant p.R297L exhibits properties very similar to those of the wild-
type enzyme. Interestingly, two other mutants reported in the
database, i.e., p.R297C and p.R297H, which are also associated with
a mild phenotype, indicate that mutations at this site are not critical
[32].
Mutant p.F382L is the one that differs most from the wild-type
enzyme. It occurs prevalently as a dimer (88.3%). Moreover, the
mutation falls in a region rich in aromatic residues. L-Phe forms
various stacking aromatic interactions with the aromatic residues
Tyr356 and Tyr277 in the wild-type enzyme [33]. The replacement by
Leu, despite the hydrophobic nature of this residue, breaks the
aromatic network and results in marked destabilization. This is in line
with larger ΔTm1 (19.6 °C) and ΔTm2 (14.0 °C) and with a lower
inactivation temperature compared to the wild-type protein (Fig. 6d).
This is the largest difference observed so far for a PAH mutant. This
highlights that L-Phe in position 382 is crucial for the stability of this
aromatic amino acid-rich region.
Lys398 is located at the tetramer interface, although it is not
directly engaged in intersubunit interactions. The positively charged
Lys is embedded in a negatively charged environment because of the
presence of Asp394 and Glu390 [43]. The high dimer/tetramer ratio
observed for mutant pK398N (75.0/17.2, Fig. 4 and Supplementary
Table S1) is in line with tetramer destabilization. Also the structural
stability was decreased. In fact, Tm1 and Tm2 were lower than that of
the wild-type enzyme being 5.6 and 4.0 °C, respectively (Table 2).
Q419 lies in a hydrated region at the dimer/tetramer interface. The
substitution of Gln by an Arg generates unfavorable ionic interactions
with a nearby Arg241 that destabilize the tetramer. The thermal
stability of p.Q419R is not signiﬁcantly affected by the mutation.
4.4. BH4 effect and the dimer–tetramer p.A403V equilibrium
In this study, we investigated the effect of BH4 on p.A403V that, in
our geographic area, is the most frequent mutant in mild, BH4-
responsive patients [32,33]. To this aim, we used the N&B technique
that has been successfully employed to discern minor changes in
molecular composition [37,38]. We monitored the ﬂuorescent
molecular forms of GFP-wild-type PAH and the GFP-A403V mutant
after transient transfection of HeLa cells. The addition of BH4 to the
1444 M. Cerreto et al. / Biochimica et Biophysica Acta 1812 (2011) 1435–1445wild-type enzyme did not cause any change. Differently, BH4 addition
to cells expressing the p.A403Vmutant promoted a shift from dimeric
to tetrameric molecular forms.
The BH4 responsiveness in HPA has been the subject of numerous
studies. Various mechanisms have been proposed to explain BH4-
responsiveness, namely: increased enzyme activity [1,30,47,48],
correction or compensation of the BH4 decreased afﬁnity, protection
toward catalytic inactivation and chaperone-like activity that, by
stabilizing the protein, protects it from proteolytic degradation
[1,15,30]. In addition, BH4 supplementation may restore the optimal
concentration of BH4 cofactor in hepatocytes [28,46]. In our study, the
N&B technique revealed that the addition of BH4 to HeLa living cells
inﬂuences the oligomerization equilibrium of the p.A403V mutant by
shifting it toward a tetrameric quaternary structure.
4.5. Concluding remarks
About 600 mutations associated with the PKU/HPA phenotype
have been identiﬁed in the PAH gene. The resulting phenotypes range
frommild to severe HPA. This study demonstrates that our seven gene
variants reduce the enzymatic activity to 38–69% of that of wild-type
activity and affect the oligomerization state, thermal stability and
folding of PAH protein. Perturbation of these biophysical and
biochemical features may, therefore, be considered major disease-
causing alterations, also in mild phenotypic forms of HPAs. In addition
to the well recognized effect of BH4 on the stability of PAH mutants
[30], we provide the ﬁrst evidence, obtained with the N&B technique,
that in cellulo exposure to BH4 inﬂuences the oligomerization
equilibrium of the p.A403V mutant. Therefore, we surmise that, in
this case, a shift from dimer to tetramer plays a major role in BH4
responsiveness.
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